Functional Precision Oncology in Fibrolamellar Carcinoma: Ex Vivo Identification of Therapeutic Vulnerabilities.

Schneider SA, D'Amora P, Evans SS, Kent P, Stockwell T, Bakaya VS, Bernard PJ, Francisco FR, Torres L, Henry J Jr, Silva IDCG, Nagourney RA

Open source

DOI
10.3390/cancers18111744
Published
2026 May 27
Container
Cancers
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/cancers18111744,
  title = {Functional Precision Oncology in Fibrolamellar Carcinoma: Ex Vivo Identification of Therapeutic Vulnerabilities.},
  author = {Schneider SA and D'Amora P and Evans SS and Kent P and Stockwell T and Bakaya VS and Bernard PJ and Francisco FR and Torres L and Henry J Jr and Silva IDCG and Nagourney RA},
  year = {2026},
  journal = {Cancers},
  doi = {10.3390/cancers18111744},
  url = {https://doi.org/10.3390/cancers18111744}
}

RIS

TY  - JOUR
TI  - Functional Precision Oncology in Fibrolamellar Carcinoma: Ex Vivo Identification of Therapeutic Vulnerabilities.
AU  - Schneider SA
AU  - D'Amora P
AU  - Evans SS
AU  - Kent P
AU  - Stockwell T
AU  - Bakaya VS
AU  - Bernard PJ
AU  - Francisco FR
AU  - Torres L
AU  - Henry J Jr
AU  - Silva IDCG
AU  - Nagourney RA
PY  - 2026
JO  - Cancers
DO  - 10.3390/cancers18111744
UR  - https://doi.org/10.3390/cancers18111744
ER  - 

APA

SA, S., P, D., SS, E., P, K., T, S., VS, B., PJ, B., FR, F., L, T., Jr, H. J., IDCG, S., & RA, N. (2026). Functional Precision Oncology in Fibrolamellar Carcinoma: Ex Vivo Identification of Therapeutic Vulnerabilities.. Cancers. https://doi.org/10.3390/cancers18111744

Source records